triazoles has been researched along with pf-4989216 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baxi, SM; Estrella, H; Li, C; Liu, KK; Mehta, PP; Smeal, T; Walls, M; Yin, MJ; Zhu, J; Zientek, M; Zong, Q | 1 |
Ambudkar, SV; Chou, AW; Hsiao, SH; Huang, YH; Hung, TH; Li, YQ; Murakami, M; Wu, CP | 1 |
2 other study(ies) available for triazoles and pf-4989216
Article | Year |
---|---|
Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, SCID; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Thiophenes; Triazoles; Xenograft Model Antitumor Assays | 2014 |
Overexpression of ATP-Binding Cassette Subfamily G Member 2 Confers Resistance to Phosphatidylinositol 3-Kinase Inhibitor PF-4989216 in Cancer Cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; MCF-7 Cells; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Thiophenes; Triazoles | 2017 |